Nicotinamide's Role in Actinic Keratosis
Author Information
Author(s): Riccardo Belardi, Francesca Pacifici, Terenzio Cosio, Sara Lambiase, Ruslana Gaeta Shumak, Fabio Artosi, Antonia Rivieccio, Danilo Cavalloro, Elena Dellambra, Luca Bianchi, David Della-Morte, Elena Campione
Primary Institution: University of Rome Tor Vergata
Hypothesis
Does nicotinamide increase serum NAD+ levels and promote SIRT1 activation in patients with actinic keratosis?
Conclusion
Nicotinamide administration significantly reduced actinic keratosis progression by enhancing NAD+ levels and SIRT1 activity.
Supporting Evidence
- Nicotinamide reduced the number and size of actinic keratosis lesions.
- Nicotinamide significantly increased serum NAD+ levels.
- Nicotinamide treatment led to enhanced nuclear SIRT1 activity.
- Patients showed a decrease in monocytes and basophils after treatment.
- Statistical analysis indicated significant results for various parameters.
Takeaway
This study shows that taking nicotinamide can help prevent skin problems caused by sun damage.
Methodology
30 patients with actinic keratosis were treated with 1000 mg of oral nicotinamide daily for 24 months, with assessments of hematological, biochemical, and skin conditions.
Potential Biases
Potential confounding factors from concomitant medications.
Limitations
Small sample size and lack of a control group.
Participant Demographics
Mean age 66.4 years, 76.5% male, with comorbidities including hypertension.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website